萊特先進生醫股份有限公司

 
  • HOME
  • ABOUT
    • Profile and History
    • Management Team
    • Business Model
    • Mission Statement
    • Awards and Certification
  • NEW DRUG
    • New Drug Development
    • BLI-1005
    • BLI-1006
    • BLI-1007
    • BLI-1008
    • BLI-1301
    • BLI-1401
  • HEALTHCARE
    • Healthcare Center
    • Dietary Supplement
  • SERVICE
    • Licensing
    • Partnering Opportunity
  • PARTNERING
    • Taiwan
    • Asia
    • Europe and United States
  • NEWS
    • Latest News
    • Press Release
  • CONTACT
    • Contact Information
    • Recruitment
  • INVESTORS

title-61-latestnews-en

 
  • Lite Biomedical Group Saluts Tenth Anniversary at 2016 Bio Taiwan
    2016-08-22
  • TNBC drug - BLI-1401-2 of BioLite, Inc. is approved by FDA to proceed phase I/II clinical trial
    2016-05-11
  • FDA approved a new ADHD drug- BLI-1008 of BioLite, Inc. to proceed phase II clinical trial
    2016-05-11
  • BioLite Inc. formed an alliance with American BriVision Corporation (ABVC) in the US
    2015-12-29
  • The huge success of 2015 International Symposium on Hematology & Oncology (ISHO)
    2015-12-29
  • BioLite, Inc. Awarded 2015 Annual Innovation Award
    2015-07-08
  • U.S. MSKCC has published the results of the phase II clinical study of Maitake mushroom extract.
    2014-11-27
  • Subvention approved during the 254th and 255th steering meeting of the Ministry of Economic Affairs under SBIR plan.
    2014-10-30
  • TFDA approved a new investigational antidepressant BLI-1005 to proceed phase 2 clinical trial.
    2014-07-08

Page 2 of 2

  • Start
  • Prev
  • 1
  • 2
  • Next
  • End
3F., No. 18, Ln. 321, Yangguang St., Neihu Dist., Taipei City 114067, Taiwan (R.O.C.)  TEL:+886 2 8751-8701   FAX:+886 2 8751-8605
Copyright ©2015 BioLite, Inc. All Rights Reserved.
 
©2026 萊特先進生醫股份有限公司 | Designed by Hurricane Media